Sept. 18 (UPI) — When it comes to controlling early symptoms of type 2 diabetes, two drugs are better than one, a new study says.
Prescribing metformin and vildagliptin to people newly diagnosed with type 2 diabetes reduced their long-term blood sugar levels more than single-drug therapy, according to findings published Wednesday in The Lancet. The patients also had lower rates of treatment failure than those who only used Metformin, the current first-line drug used by new type 2 diabetics.
“The findings of VERIFY support and emphasize the importance of achieving and maintaining early glycaemic control,” the authors wrote.
Comments are closed.